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A Mycoplasma hyopneumoniae clone bank was screened with hyperimmune pig serum. One clone exhibited
sequence homology to the prokaryotic R2 subunit of ribonucleotide reductase and was expressed as an 11-kDa
protein fused to b-galactosidase. The vaccine potential of the fusion protein was assessed in pig trials.
Following experimental challenge with a virulent isolate of M. hyopneumoniae, gross lung pathology (mean
Goodwin lung score) of vaccinated animals, irrespective of adjuvant treatment, was significantly reduced
compared with that of control unvaccinated pigs (P < 0.05).
Mycoplasma hyopneumoniae is the causative agent of por-
cine enzootic pneumonia, a chronic respiratory disease which
affects between 30 and 80% of pigs (33) and inflicts severe
economic burden on pig producers through reduced growth
rates (8, 16, 24, 27). Pigs previously infected with M. hyopneu-
moniae recover with time and are highly resistant to subse-
quent reinfection (18, 19). Bacterins with proven efficacy have
been developed for the control of porcine enzootic pneumonia
(5, 23, 25); however, variation in efficacy of such vaccines, the
cost of components, and the labor-intensive mode of delivery
may in practice prove them to be cost prohibitive. In this report
we describe the molecular and immunological analysis of an
11-kDa antigen with amino acid sequence homology to the R2
subunit of the prokaryotic class I ribonucleotide reductases.
This recombinant vaccine has been shown to protect pigs from
lung damage when assessed after experimental challenge with
virulent M. hyopneumoniae.
M. hyopneumoniae J, the virulent Beaufort strain of M. hyo-
pneumoniae, Mycoplasma hyorhinis GDL, and Mycoplasma
flocculare Ms42 were provided by A. Pointon (Central Veter-
inary Laboratory, Adelaide, Australia). Porcine mycoplasmas
were cultured in modified Friis medium (32). Chromosomal
DNA was extracted by the method of Razin et al. (28). A
recombinant gene library was constructed by ligating Sau3AI-
digested M. hyopneumoniae J chromosomal DNA into the
BamHI site of the expression plasmids pEX1 to pEX3 (35).
Ligation into this site fuses the inserted fragment to the 39 end
of the lacZ gene, resulting in an open reading frame which, if
in phase, will be expressed as a hybrid b-galactosidase protein.
After transformation into Escherichia coli MC1061(pCI857)
(22), recombinant colonies were induced at 428C for 2 h, lysed,
and then screened for recombinant protein expression with
porcine hyperimmune M. hyopneumoniae antiserum (32). A
positive clone containing a 0.8-kb DNA insert was isolated and
designated pSD9. Following heat induction at 428C, Western
blotting (immunoblotting) (1, 20, 30) of E. coli MC1061
(pCI857, pSD9) whole-cell extracts with porcine hyperimmune
M. hyopneumoniae antiserum localized a strongly immunore-
active band at 128 kDa consisting of b-galactosidase (117 kDa)
and a recombinant M. hyopneumoniae protein (11 kDa). The
same antiserum did not react against E. coli MC1061(pCI857,
pEX1) (results not shown). The 128-kDa protein was purified
by urea extraction (15) and used to generate rabbit polyclonal
antiserum for immunological analysis (12). Cross-reactivity
against b-galactosidase was minimized by extensive absorption
with b-galactosidase-impregnated nitrocellulose. Coomassie
blue R250 staining of sodium dodecyl sulfate-polyacrylamide
gels and Western blot analysis (using the rabbit antiserum) of
E. coli cells containing pSD9 detected the 128-kDa fusion
protein (Fig. 1, lanes 3), whereas E. coli MC1061(pCI857,
pEX1) expressed only b-galactosidase (Fig. 1, lanes 2). Resid-
ual activity against b-galactosidase was observed after preab-
sorption of the rabbit antiserum in the Western blot analysis
(Fig. 1B, compare lanes 2 and 3). Immunoreactive bands of
less than 128 kDa identified in Fig. 1B, lanes 3 and 4, are most
likely due to the presence of breakdown products of the 128-
kDa fusion protein. In whole-cell M. hyopneumoniae protein
preparations a single 42-kDa protein was identified by Western
blot analysis (Fig. 1B, lane 5). The specificity of the 42-kDa
protein in the Western blot was shown to be due to the M.
hyopneumoniae component of the fusion protein, as no cross-
reactivity was found with rabbit b-galactosidase antiserum
against the 42-kDa M. hyopneumoniae protein (results not
shown).
The 0.8-kb DNA fragment was cloned into pHSG398 (36) to
form pKF1. This plasmid was used as a template to determine
the complete nucleotide sequence (31) for both strands of the
M. hyopneumoniae DNA fragment. The sequence length was
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found to be 822 bp with a GC content of 30.0%, which is typical
of mycoplasmal genomes (13). Translation analysis of the
0.8-kb sequence revealed the presence of three open reading
frames, designated nrdF, ORF2, and ORF3 (Fig. 2B). The
nrdF gene is incomplete at the 59 end, is read in frame with the
b-galactosidase protein, is 96 amino acids in length, and ends
with a TAA stop codon. A region of dyad symmetry which may
act as a transcriptional terminator was not found downstream
of nrdF, suggesting that nrdF and ORF2 are organized in an
operon. The conserved 8-nucleotide sequence 59-ATTGGGA
G-39 is present 7 nucleotides upstream of the ATG methionine
start codon of ORF2 and ORF3. In both cases the intervening
sequence is composed exclusively of A and T residues, indic-
ative of mycoplasma ribosome binding sites (9, 37, 40). This
sequence contains 4 nucleotides which can base pair with the
conserved sequence 39-CCUCCA-59 at the 39 end of the M.
hyopneumoniae 16S rRNA. This degree of homology is con-
sidered sufficient to initiate translation in E. coli (37).
The translated product of nrdF shows homology to the NrdF
protein of Salmonella typhimurium (17) (EMBL accession
number X73226), an open reading frame product which is
encoded by the 59 region of the proU operons of E. coli and S.
typhimurium (EMBL accession number X52693) (4, 11, 21).
The putative M. hyopneumoniae NrdF protein also demon-
strates homology to an open reading frame product encoded
by the esf2 random clone sequence of Mycoplasma genitalium
(GenBank accession number U01739) (26). Homology com-
parisons scoring identical amino acids (Fig. 3) between the M.
hyopneumoniae NrdF protein and the S. typhimurium and E.
coli proteins gives 48.4 and 51.5%, respectively; if conserved
amino acids are considered, the homology rises to 86.6 and
87.6%, respectively. The translated product of M. hyopneu-
moniae nrdF has 75.0% homology (97.9% if conserved amino
acids are considered) to the protein encoded by esf2. In all the
above reading frames the protein terminates with the same
carboxy-terminal amino acid. The 59 proU sequences of S.
typhimurium and E. coli (4, 11, 21) correspond to the S. typhi-
murium nrdF sequence (17) and should therefore be consid-
ered to be the same gene. S. typhimurium NrdF functions as an
R2 ribonucleotide reductase subunit; this class of enzymes is
responsible for the conversion of ribonucleotides to deoxyri-
bonucleotides for use in DNA synthesis (38). S. typhimurium
NrdF can also detoxify hydroxyurea, thus conferring resistance
against this potent DNA synthesis inhibitor (17, 29). The 42-
kDa protein identified in this study may play a similar role in
M. hyopneumoniae. There was no significant protein homology
between the putative M. hyopneumoniae protein encoded by
ORF2 and other known protein sequences deposited in Gen-
Bank. ORF3 is incomplete at the carboxyl terminus and is
composed of only 8 amino acids. However, the presence of the
conserved putative ribosome binding site and a putative 210
promoter sequence (59-TATAAT-39) 33 bp upstream of the
ATG start codon of ORF3 indicates that this is the beginning
of a new open reading frame (Fig. 2). As for the rrn promoter
of M. hyopneumoniae, a 235 consensus sequence was not
found upstream of the ORF3 210 sequence (37).
Southern hybridization analysis (34) of M. hyopneumoniae
(strain J), M. flocculare (strain Ms42), and M. hyorhinis (strain
GDL) chromosomal DNA (Fig. 4A) was carried out using the
0.8-kb M. hyopneumoniae DNA fragment as a probe. This
DNA probe hybridized strongly to a 2.45-kb HindIII-restricted
M. hyopneumoniae chromosomal fragment and reacted weakly
against a 5.7 kb-HindIII-restricted M. flocculare chromosomal
fragment (Fig. 4B). Following overexposure of the autoradio-
graph, the 0.8-kb fragment hybridized with an M. hyorhinis
chromosomal DNA fragment of 2.6 kb (result not shown).
PCR (30) primers 1469 (59-TTTGCCGAACCTTTTTACA-39)
and 1470 (59-AATCAGCAATAAAATTTAGC-39) generated
a 750-bp PCR product from M. hyopneumoniae chromosomal
DNA (Fig. 4C). Under all conditions in which amplification of
the 750-bp fragment was achieved with M. hyopneumoniae
DNA, an identically sized fragment was amplified with M.
flocculare chromosomal DNA as a template (Fig. 4C). Thus,
although these primers clearly differentiate between M. hyo-
pneumoniae and M. hyorhinis reference strains, the usefulness
of such primers for routine diagnosis is limited because of
cross-reaction with M. flocculare.
The M. hyopneumoniae NrdF fusion protein was purified
after induction of E. coli MC1061(pCI857, pSD9) for 3 h at
428C. Induced cells were collected, reduced, and fractionated
with a 491 Bio-Rad PrepCell column (37-mm internal diame-
ter) containing a 5% polyacrylamide matrix with a 4% stacking
gel. Fractions (10 ml) were routinely monitored for the elution
of the 128-kDa NrdF fusion protein by Western blotting using
rabbit NrdF fusion protein antiserum. Samples containing the
NrdF fusion protein were pooled and concentrated by ultrafil-
tration. NrdF fusion protein stock antigen for vaccination stud-
ies was estimated by measuring the A280 to contain 4.4 mg of
protein per ml of PBST buffer (phosphate-buffered saline
[PBS; pH 7.2], 0.2% [vol/vol] Tween 80), except for algammu-
lin-based vaccines, which were prepared phosphate free and
utilized the same stock concentration of NrdF fusion protein
FIG. 1. Expression and identification of the M. hyopneumoniae fusion pro-
tein. (A) Coomassie brilliant blue-stained 11% polyacrylamide gel. Lane 1,
MC1061(pCI857); lane 2, MC1061(pCI857, pEX1) (induced); lane 3,
MC1061(pCI857, pSD9) (induced); lane 4, purified M. hyopneumoniae 128-kDa
fusion protein; lane 5, whole-cell extract of M. hyopneumoniae J. Positions of
molecular size standards (in kilodaltons) and the M. hyopneumoniae 128-kDa
fusion protein are indicated. (B) Western blot analysis of equivalent protein
samples described for panel A using rabbit M. hyopneumoniae 128-kDa fusion
protein antiserum. The positions of molecular size markers and the 42-kDa
wild-type protein present in M. hyopneumoniae whole-cell extracts are indicated.











solubilized in 0.85% NaCl containing 0.2% (vol/vol) Tween 80
(pH 7.4). Pigs (n 5 18) used for vaccination studies were from
an M. hyopneumoniae-free piggery and were randomly allo-
cated into pens of 4 to 5 pigs. All pigs were housed in an
experimental piggery which had no other resident pigs and
were fed an antibiotic-free commercial pelleted grower ration.
Pigs (n 5 12) were inoculated intramuscularly at 42 and 75
days of age with NrdF fusion protein (1 mg per pig) complexed
with one of four different adjuvants (3 pigs per adjuvant):
alhydrogel (Cyanamid Websters), algammulin (3), DEAE-dex-
tran-mineral oil (14), and DEAE-dextran-Auspharm vegetable
oil (Auspharm International). All pigs, including six control
animals, were challenged at 85 days of age with 20 ml of lung
homogenate (equivalent to 9.2 g [wet weight] in 20 ml of PBS
per pig) containing the virulent Beaufort strain (7) of M. hyo-
pneumoniae. Prior to challenge, all pigs were sedated with
FIG. 2. DNA sequence analysis of the cloned 0.8-kb M. hyopneumoniae chromosomal DNA fragment. (A) Diagrammatic representation of the strategy used to
obtain the nucleotide sequence of the 0.8-kbM. hyopneumoniae DNA fragment (shaded). Filled arrows indicate the positions of open reading frames, the first of which
has sequence homology to the nrdF gene of S. typhimurium. Thin arrows indicate the extent of the sequence reaction from synthesized oligonucleotide primers. The
open arrows indicate the positions of putative M. hyopneumoniae ribosome binding sites, while the keyhole symbol indicates the presence of inverted repeats. Scale is
given underneath in base pairs. (B) Nucleotide sequence of the M. hyopneumoniae DNA fragment. Three open reading frame products are given three-letter amino
acid codes. Underlining denotes the conserved 8-nucleotide sequence which is 7 bases upstream of the ATG start codons. Dashed arrows above the sequence indicate
an inverted repeat structure.











azaperone and anesthetized by induction with halothane and
nitrous oxide via face mask and then more deeply anesthetized
(sufficient for intubation) with thiopentone (3.5 mg/kg of body
weight) given through a marginal ear vein. Animals were
weighed weekly and slaughtered at 126 days of age, when lungs
were collected for Goodwin lung scoring (10). Samples of
infected lung containing lesions were cultured for the bacteria
Pasteurella multocida (2) and Actinobacillus pleuropneumoniae
(39), which are commonly associated with porcine pneumonia;
neither organism was detected. The effects on lung score of
vaccination and of adjuvants within the vaccinated groups were
assessed in an analysis of variance of logistic-transformed
scores in which tests of significance were performed using an
estimate of experimental error pooled from this and four sim-
ilar trials (6). Pigs vaccinated with NrdF fusion protein (n 5
12) had a significantly lower (P , 0.05) mean logistic-trans-
formed lung score (mean lung score 5 8.0; 22.02 6 0.27
standard error) than the unvaccinated controls (n 5 6) (mean
lung score 5 15.3; 20.97 6 0.38 standard error), but there
were no significant differences detected among the four adju-
vant groups (alhydrogel, algammulin, DEAE-dextran-mineral
oil, and DEAE-dextran-Auspharm vegetable oil). The mean
average daily live weight gain of vaccinates (0.562 6 0.024
kg/day) was not significantly greater (P. 0.05) than that of the
controls (0.506 6 0.034 kg/day), and no significant differences
in gain were detected among the four adjuvant treatment
groups. We are currently assessing the protective efficacy of the
11-kDa NrdF antigen in combination with other antigens de-
rived from M. hyopneumoniae.
While a number of bacterins are currently available or under
evaluation for the control of porcine enzootic pneumonia (5,
23, 25), the particle size of such vaccines precludes entrapment
within certain novel adjuvant delivery systems which can target
specific arms of the effector immune system. Identification and
cloning of protective antigens of M. hyopneumoniae provide
the basis for the development of new generation vaccines
against enzootic pneumonia.
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FIG. 3. Sequence homology for the M. hyopneumoniae (M.h) NrdF 11-kDa
protein aligned with the product of the gene immediately upstream of the E. coli
proU (E.c) operon, S. typhimurium NrdF protein (S.t), and M. genitalium esf2
gene product (M.g). Homology to identical amino acids is 51.5, 48.4, and 75.0%,
respectively; however, when conserved amino acids are considered, homology
rises to 87.6, 86.6, and 97.9%, respectively. Amino acids are given in one-letter
codes. Identical amino acids are in boldface capital letters, conserved amino
acids are in underlined boldface lowercase letters, and variant amino acids are
denoted by lowercase letters. DNA sequences were compared by using the
Australian National Genomic Information Service to search the GenBank se-
quence database. Homology was calculated with the MacVector sequence anal-
ysis program, version 3.5 (IBI-Kodak).
FIG. 4. Southern hybridization and PCR analysis of M. hyopneumoniae
DNA, M. hyorhinis DNA, and M. flocculare DNA. (A and B) Lanes 1, M. hyo-
pneumoniae chromosomal DNA digested with HindIII; lanes 2, M. hyorhinis
chromosomal DNA digested with HindIII; lanes 3, M. flocculare chromosomal
DNA digested with HindIII. Molecular size markers (in kilobases) are indicated.
(A) Ethidium bromide-stained 1% agarose gel; (B) Southern hybridization anal-
ysis using the 0.8-kb DNA fragment as a probe. Arrows indicate the 2.45-kb
HindIII M. hyopneumoniae DNA fragment and 5.7-kb M. flocculare HindIII
fragment. (C) PCR amplification of porcine mycoplasma DNA using primers
1469 and 1470, which target the M. hyopneumoniae 0.8-kb DNA fragment.
Genomic DNAs from M. hyopneumoniae, M. hyorhinis, and M. flocculare (lanes
1 to 3, respectively) were used as templates for the PCR. Lane 4 is a control
without a template. The hybridization temperature used was 558C. Molecular
size markers (in kilobases) and the 0.8-kb PCR products are indicated.
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